Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2008-04-22
2008-04-22
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S188100
Reexamination Certificate
active
10420438
ABSTRACT:
Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a compound that binds to the apical cleft near the C-terminal end of the N-terminal domain of the HIV-1 capsid protein are provided. Derivatives of CAP-1, CAP-2, CAP-3, CAP-4, CAP-5, CAP-6 and CAP-7 are described that bind to the apical cleft of the N-terminal domain of the HIV-1 capsid protein and inhibit proper assembly of the core particle.
REFERENCES:
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5716929 (1998-02-01), Bemis et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5843904 (1998-12-01), Bemis et al.
patent: 6008217 (1999-12-01), Batchelor et al.
patent: 6025147 (2000-02-01), Bemis et al.
patent: 6103711 (2000-08-01), Bemis et al.
patent: 6162790 (2000-12-01), Bemis et al.
patent: 2001/0036627 (2001-11-01), Prevelige
patent: 2002/0094523 (2002-07-01), Sakalian et al.
patent: 2003/0104577 (2003-06-01), Lingappa et al.
Fitzon, Leschonsky, Bieler, Paulus, Schroder, Wolf and Wagner (2000), Virology, 268, 294-307.
Dorfman and Gottlinger (1996) Journal of Virology. (70)9:5751-5757.
von Schwedler et al (1998). EMBO Journal. 17(6): 1555-1568.
Gamble et al (1996). Cell. 87: 1285-1294.
Coffin, J., “HIV Population Dynamic In vivo: Implications for Genetic Variation ,Pathogenesis and Therapy, Science” 267:483-89 (1995).
Forshey, et al., “Formation of a Human Immunodeficiency Virus Type 1 Core of Optimal Stability is Crucial for Viral Replication”, J. virol. 76:5667-5677 (2002).
Gitti, et al., “Structure of the amino-terminal core domain of the HIV-1 capsid protein”, Science, 273:231-35 (1996).
Gross, et al., “N-terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles”, J. Virol., 72: 4798-4810 (1998).
Huang, et al., “p6Gag is required for particle production from full length human immunodeficiency virus type 1 molecular clones expressing protease”, J. Virol., 96:6810-18 (1995).
Kimpton, et al., “Detection of a replication-competent and pseudotyped HIV with a sensitive cell line on the basis of activation of an integrated B-galactosidase gene”, J. Virol. 66: 2232-39 (1992).
Kuritzkes, D. R., “Clinical significance of drug resistance in HIV-1 infection” AIDS 10:S27-33 (1996).
Mansky, et al., “Combination of drugs and drug resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies”, J. Virol., 76:9253-59 (2002).
O'Brien et al. “HIV causes AIDS: Koch's postulates fulfilled”, Curr Opin Immunol 8:613 (1996).
Pillay, et al., “Incidence and impact of resistance against approved antiretroviral drugs”, Rev Med Virol, 10:231-53 (2000).
Reicin, et al., “The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle”., J. Virol., 70:8645-52 (1996).
Richman, D.D., HIV chemotherapy, Nature 410:995-1001 (2001).
Smith, et al., “The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating”, Science, 233: 1286-93 (1986).
Tang, et al. “Antiviral Inhibition of the HIV-1 Capsid Protein”, J. Mol. Biol 327:1013-1020 (2003).
Tang, et al., “Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology are blocked in initiation of reverse transcription in infected cells”, J. Virol. 75:9357-66 (2001).
Von Schwedler, et al., “Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly”, EMBO J., 17:1555-68 (1998).
Billich et al., “Mode of Action of SDZ NIM 811, a Nonimmunosuppressive Cyclosporin A Analog with Activity against Human Immunodeficiency Virus (HIV) Type 1: Interference with HIV Protein-Cyclophilin A Interactions” Journal of Virology, 69:4 (1995) pp. 2451-2461.
Campos-Olivas et al., “Backbone Dynamics of the N-Terminal Domain of the HIV-1 Capsid Protein and Comparison with the G94D Mutant Conferring Cyclosporin Resistance/Dependence” Biochemistry 38 (1999) pp. 10262-10271.
Chatterji et al., “Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-Cyclophilin-resistant in Owl Monkey Cells” J. Biol. Chem. 280: 48 (2005) pp. 40293-40300.
Thali et al., “Functional Association Cyclophilin A with HIV-1 Virions” Nature 372 (1994) pp. 363-365.
Turner et al., “Structural Biology of HIV” J. Mol. Biol. 285 (1999) pp. 1-32.
Huang Mingjun
Summers Michael F.
Tang Chun
Campell Bruce R.
Horning Michelle
University of Maryland Baltimore County
Wilmer Cutler Pickering Hale & Dorr LLP
LandOfFree
Antiviral inhibition of capsid proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral inhibition of capsid proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral inhibition of capsid proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3953503